Semaglutide capacity (sterile days per line)
225 days
+0% YoY
Each line provides ~225 sterile manufacturing days; three lines will yield ~675 days by FY27-end.
ONESOURCESPECIALTYPHARMA
Healthcare
30 Apr 2026
Onesource Specialty Pharma Ltd — Q4 FY26
Onesource Specialty Pharma delivered a strong Q4 FY26 recovery with revenue of ₹428.2 crore (up 47% QoQ) and EBITDA of ₹91.9 crore (up >5x QoQ), driven by the start of commercial shipments of generic semaglutide drug-device combinations in India and Canada.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Onesource Specialty Pharma delivered a strong Q4 FY26 recovery with revenue of ₹428.2 crore (up 47% QoQ) and EBITDA of ₹91.9 crore (up >5x QoQ), driven by the start of commercial shipments of generic semaglutide drug-device combinations in India and Canada. The company reaffirmed its FY28 guidance of $400 million revenue with ~40% EBITDA margins, supported by capacity expansion (second line online in Q2, third by year-end) and a robust demand pipeline across regulated and emerging markets. Biologics funnel expanded 4x YoY, adding key partnerships. The related-party transaction with Ster Science was deferred due to valuation concerns from minority shareholders. Key risk: any delay in regulatory approvals or capacity ramp-up could temper the sequential growth trajectory.
Key Numbers
Biologics funnel expansion
4x
+300% YoY
Biologics customer funnel expanded four times versus previous year, with new US and European biosimilar partners.
Customer base share of Indian generic semaglutide market
~67%
New metric
As of end-April, customers represent nearly two-thirds of the Indian generic semaglutide market by value.
Regulatory and customer audits completed
49
+0% YoY
Completed 49 regulatory and customer audits in FY26, including surprise FDA inspections with zero observations.
Management Guidance
FY28 revenue target of $400 million
Reaffirmed organic revenue guidance of $400 million for FY28, driven by semaglutide DDC and base business growth.
Management guidance revenueFY28 EBITDA margin target of ~40%
Reaffirmed EBITDA margin guidance of approximately 40% for FY28, supported by operating leverage from capacity expansion.
Management guidance marginsSecond DDC line commercial in Q2 FY27
The second drug-device combination line is undergoing qualification and will be available for commercial manufacturing from Q2 FY27.
Management guidance expansionThird DDC line by end of FY27
A third DDC line will be installed and operational by the end of FY27, bringing total lines to three.
Management guidance expansionKey Risks
Minority shareholder opposition to related-party transaction
The proposed scheme to acquire Ster Science injectables business was deferred due to valuation concerns from a long tail of smaller investors, despite majority support.
medium · management_commentaryDependence on customer regulatory approvals for revenue ramp
Revenue growth relies on customers obtaining regulatory approvals in various markets; delays could impact sequential improvement.
medium · analyst_questionCapacity ramp-up execution risk
New lines must be qualified and validated on time; any delays could constrain ability to meet robust demand.
medium · data_observationOral semaglutide competition
Oral GLP-1 formulations could capture up to a third of the market, potentially reducing demand for injectable formulations.
low · analyst_questionNotable Quotes
We are the first and the only CDMO partner for the first three generic semaglutide approvals in all the highly regulated markets US and Canada.
We decided to defer this transaction until such time both One Source delivers on its 400 million and the incoming assets deliver on its 40 million of EBIT.
The biggest challenge actually for the customers is access to capacity... customers have done a capacity reservation with us including take or pay kind of contract.
Frequently Asked Questions
What was Onesource Specialty Pharma's revenue in Q4 FY26?
Onesource Specialty Pharma reported revenue of ₹428 Cr in Q4 FY26, representing a — change compared to the same quarter last year.
What guidance did Onesource Specialty Pharma management give for FY27?
FY28 revenue target of $400 million: Reaffirmed organic revenue guidance of $400 million for FY28, driven by semaglutide DDC and base business growth. FY28 EBITDA margin target of ~40%: Reaffirmed EBITDA margin guidance of approximately 40% for FY28, supported by operating leverage from capacity expansion. Second DDC line commercial in Q2 FY27: The second drug-device combination line is undergoing qualification and will be available for commercial manufacturing from Q2 FY27. Third DDC line by end of FY27: A third DDC line will be installed and operational by the end of FY27, bringing total lines to three.
What are the key risks for Onesource Specialty Pharma in FY27?
Key risks include Minority shareholder opposition to related-party transaction — The proposed scheme to acquire Ster Science injectables business was deferred due to valuation concerns from a long tail of smaller investors, despite majority support.; Dependence on customer regulatory approvals for revenue ramp — Revenue growth relies on customers obtaining regulatory approvals in various markets; delays could impact sequential improvement.; Capacity ramp-up execution risk — New lines must be qualified and validated on time; any delays could constrain ability to meet robust demand.; Oral semaglutide competition — Oral GLP-1 formulations could capture up to a third of the market, potentially reducing demand for injectable formulations..
Did Onesource Specialty Pharma meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Onesource Specialty Pharma Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.